share_log

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

In8Bio將出席諾布爾資本市場新興增長虛擬醫療股票會議
In8bio ·  04/16 12:00

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.

紐約,2024 年 4 月 16 日(GLOBE NEWSWIRE)— in8Bio, Inc. 納斯達克股票代碼:INAB)是一家開發創新伽瑪-德爾塔T細胞療法的臨床階段生物製藥公司,今天宣佈,首席執行官兼聯合創始人William Ho將於4月18日星期四出席諾布爾資本市場的新興增長虛擬醫療保健股票會議第四 美國東部時間下午 12:30。

The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Attendees interested in viewing the live presentation can register for this event here: Virtual Healthcare Equity Conference Registration.

正式演講將以爐邊風格的問答環節爲特色,歡迎現場虛擬觀衆提問。有興趣觀看現場演示的與會者可以在此處註冊此活動: 虛擬醫療保健股權會議註冊

The IN8bio management team will also be hosting one-on-one meetings during the virtual event with registered, qualified investor attendees. Interested parties should contact their Noble representative to schedule a meeting.

In8bio管理團隊還將在虛擬活動期間與註冊的合格投資者舉行一對一的會議。有關各方應聯繫其Noble代表以安排會議。

A video webcast of the presentation will be available following the event on the Company's website https://investors.in8bio.com/news-events/events-presentations, and as part of a complete catalog of presentations available on Channelchek www.channelchek.com, the investor portal created by Noble. The webcast will be archived on the company's website and on Channelchek.com for 90 days following the event.

活動結束後,將在公司網站上提供該演講的網絡視頻直播 https://investors.in8bio.com/news-events/events-presentations,也作爲 Channelchek 上提供的完整演示文稿目錄的一部分 wwwchannelchek.com,由諾布爾創建的投資者門戶網站。網絡直播將在活動結束後的90天內在公司網站和ChannelChek.com上存檔。

About IN8bio

關於 in8Bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com.

in8bio是一家臨床階段的生物製藥公司,爲癌症患者開發基於伽瑪-德爾塔T細胞的免疫療法。gamma-delta T 細胞是一組特殊的 T 細胞,具有獨特的特性,包括區分健康組織和病變組織的能力。該公司的牽頭項目 INB-400 正在進行多形性膠質母細胞瘤(GBM)的二期試驗。其他項目包括實體腫瘤和血液學腫瘤的 1 期試驗,包括針對 GBM 的 INB-200 和針對接受移植的血液系統惡性腫瘤患者的 INB-100。有關in8bio的更多信息,請訪問www.in8bio.com。

About Noble Capital Markets, Inc.

關於諾布爾資本市場有限公司

Noble Capital Markets ("Noble") is a research driven investment bank that has supported small & microcap companies since 1984. As a FINRA and SEC licensed broker dealer Noble provides institutional-quality equity research, merchant and investment banking, and order execution services. In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade. Noble launched www.channelchek.com in 2018 - an investor community dedicated exclusively to public small and micro-cap companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 6,000 public emerging growth companies are listed on the site, with growing content including research, webcasts, podcasts, and balanced news.

諾布爾資本市場(“Noble”)是一家以研究爲導向的投資銀行,自1984年以來一直爲小型和微型股公司提供支持。作爲FINRA和SEC的持牌經紀交易商,Noble提供機構質量的股票研究、商業和投資銀行以及訂單執行服務。2005年,諾布爾成立了NobleCon,該投資者會議在過去十年中取得了長足的發展。Noble 推出 wwwchannelchek.com 2018年——一個專門關注上市小型和微型股公司及其行業的投資者社區。Channelchek是第一家向公衆提供機構質量研究的服務,無需訂閱即可免費提供各個級別的研究。該網站上列出了6,000多家上市新興成長型公司,內容不斷增加,包括研究、網絡廣播、播客和平衡新聞。

Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com

公司聯繫人:
in8Bio, Inc.
格倫·舒爾曼,藥學博士,公共衛生碩士
203.494.7411
gdschulman@IN8bio.com

Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

投資者
梅魯顧問
李 M. 斯特恩
lstern@meruadvisors.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

媒體聯繫人
金伯利哈
KKH 顧問
917.291.5744
kimberly.ha@kkhadvisors.com

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論